Open AccessClinical outcomes at 1 year in early Psoriasis Area and Severity Index responders compared with non‐responders: Subgroup analysis of UNCOVER‐3 trial
Author(s) -
Rosmarin D.,
Smith S.,
Shrom D.,
Burge R.,
See K.,
McKeanMatthews M.,
Ridenour T.,
Lin C.Y.,
Gorelick J.
Publication year - 2021
Publication title -
skin health and disease
Language(s) - English
Resource type - Journals
ISSN - 2690-442X
DOI - 10.1002/ski2.43
Subject(s) - etanercept , medicine , psoriasis area and severity index , ixekizumab , psoriasis , placebo , adalimumab , randomized controlled trial , dermatology life quality index , clinical trial , secukinumab , tumor necrosis factor alpha , immunology , psoriatic arthritis , alternative medicine , pathology